Philadelphia Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Philadelphia Pharmaceuticals has a total shareholder equity of JOD12.7M and total debt of JOD1.5M, which brings its debt-to-equity ratio to 11.7%. Its total assets and total liabilities are JOD16.0M and JOD3.3M respectively. Philadelphia Pharmaceuticals's EBIT is JOD1.4M making its interest coverage ratio 4. It has cash and short-term investments of JOD1.4M.
Key information
11.7%
Debt to equity ratio
د.أ1.49m
Debt
| Interest coverage ratio | 4x |
| Cash | د.أ1.40m |
| Equity | د.أ12.74m |
| Total liabilities | د.أ3.28m |
| Total assets | د.أ16.03m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PHIL's short term assets (JOD10.1M) exceed its short term liabilities (JOD3.3M).
Long Term Liabilities: PHIL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PHIL's net debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: PHIL's debt to equity ratio has reduced from 12.9% to 11.7% over the past 5 years.
Debt Coverage: PHIL's debt is well covered by operating cash flow (73.7%).
Interest Coverage: PHIL's interest payments on its debt are well covered by EBIT (4x coverage).